Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not.
Stephenson
J M
JM
Department of Sexually Transmitted Diseases, University College, London Medical School, UK.
Williams
I G
IG
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D017828:Rifabutin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017828:Rifabutin